Risk factor analyses established the detection of minimal disseminated disease (MDD) in bone marrow (BM) or peripheral blood (PB) by qualitative RT-PCR for NPM-ALK fusion transcripts, small-cell or lymphohistiocytic patterns and low anti-ALK antibody titers as independently associated with treatment failure [3,4]. The gene discussed is ALK; the disease is major depressive disorder.